드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

비급여
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

제품성상

미황색-황색의 투명한 겔 [제형정보 확인]

포장·유통단위

10g

효능효과

[적응증 별 검색]

여드름

약물음식간 상호작용

[조회]

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
일반적으로 1일 1회 저녁에 세면 후 건조한 후 감염부위에 사용한다. 과량사용은 피부의 자극반응을 유발하는 결과가 나타날 수 있다. 본제를 사용한 후 반드시 손을 세척하여야 한다. 본제 소량을 환부에 바르고 손가락 끝으로 침투가 될 때까지 잘 문지른다.

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

주요약물 상호작용

[조회]

금기

본제에 과민증인 환자 또는 마크로라이드계에 과민증 환자
피부상피종이 있거나 가족기왕력자
습진, 절상, 찰과상이 있는 환자
햇볕에 탄환자는 완전히 회복될 때까지 본제를 사용하지 않는다.
임부, 수유부 및 가임 여성은 사용하지 않는다.

이상반응

개인에 따라 민감한 피부는 건조감, 가려움증, 박리, 작열감, 홍반, 발적, 부종, 포진 또는 가피층이 나타날 수 있으므로 이런 경우에는 본제의 사용을 조절하거나 중지한다.
연용할 경우 일시적인 과다 또는 과소 색소침착이 일어난다는 보고가 있다.
드물게 접촉성 알러지가 보고되어 있다.
태양광선에 대한 감수성이 증대될 수 있다.
바람이나 추위 등 극한 날씨에는 환자에게 자극이 될 수 있다.

드물게 발진 등이 나타날 수 있으므로 이러한 경우에는 투여를 중지한다.

[주요 이상반응정보]

상호작용

설파제, 레소르시놀, 과산화벤조일, 살리실산, 클린다마이신 및 린코마이신 등과 병용할 경우 본제와 상호작용이 있어날 수 있으므로 주의해서 사용한다.
각질 용해제를 사용한 환자는 그 약의 효과가 없어진 후에 본제를 사용한다.
약용비누, 연마비누, 세척제 그리고 강력한 건조작용을 가지고 있는 화장품, 고농도의 알코올을 함유한 제제나 수렴제, 향신료 또는 석회 등은 본제와 작용을 할 가능성 때문에 주의해서 사용한다.

Off-label Usage

[조회]

Related FDA Approved Drug

기준 성분:TRETINOIN
ACCUTANE (ISOTRETINOIN)
AMNESTEEM (ISOTRETINOIN)
ATRALIN (TRETINOIN)
AVITA (TRETINOIN)
CLARAVIS (ISOTRETINOIN)
PANRETIN (ALITRETINOIN)
RENOVA (TRETINOIN)
RETIN-A (TRETINOIN)
RETIN-A MICRO (TRETINOIN)
SOLAGE (MEQUINOL; TRETINOIN)
SOTRET (ISOTRETINOIN)
TRETINOIN (TRETINOIN)
TRI-LUMA (FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN)
VESANOID (TRETINOIN)
ZIANA (CLINDAMYCIN PHOSPHATE; TRETINOIN)
기준 성분:ERYTHROMYCIN
A/T/S (ERYTHROMYCIN)
AKNE-MYCIN (ERYTHROMYCIN)
BENZAMYCIN (BENZOYL PEROXIDE; ERYTHROMYCIN)
BENZAMYCIN PAK (BENZOYL PEROXIDE; ERYTHROMYCIN)
BRISTAMYCIN (ERYTHROMYCIN STEARATE)
C-SOLVE-2 (ERYTHROMYCIN)
E.E.S. (ERYTHROMYCIN ETHYLSUCCINATE)
E.E.S. 200 (ERYTHROMYCIN ETHYLSUCCINATE)
E.E.S. 400 (ERYTHROMYCIN ETHYLSUCCINATE)
E-BASE (ERYTHROMYCIN)
E-GLADES (ERYTHROMYCIN)
EMGEL (ERYTHROMYCIN)
E-MYCIN (ERYTHROMYCIN)
E-MYCIN E (ERYTHROMYCIN ETHYLSUCCINATE)
ERYC (ERYTHROMYCIN)
ERYC 125 (ERYTHROMYCIN)
ERYC SPRINKLES (ERYTHROMYCIN)
ERYCETTE (ERYTHROMYCIN)
ERYDERM (ERYTHROMYCIN)
ERYGEL (ERYTHROMYCIN)
ERYMAX (ERYTHROMYCIN)
ERYPAR (ERYTHROMYCIN STEARATE)
ERYPED (ERYTHROMYCIN ETHYLSUCCINATE)
ERY-TAB (ERYTHROMYCIN)
ERYTHRA-DERM (ERYTHROMYCIN)
ERYTHROCIN (ERYTHROMYCIN LACTOBIONATE)
ERYTHROCIN STEARATE (ERYTHROMYCIN STEARATE)
ERYTHROMYCIN (ERYTHROMYCIN)
ERYTHROMYCIN AND BENZOYL PEROXIDE (BENZOYL PEROXIDE; ERYTHROMYCIN)
ERYTHROMYCIN ESTOLATE (ERYTHROMYCIN ESTOLATE)
ERYTHROMYCIN ETHYLSUCCINATE (ERYTHROMYCIN ETHYLSUCCINATE)
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
ERYTHROMYCIN LACTOBIONATE (ERYTHROMYCIN LACTOBIONATE)
ERYTHROMYCIN STEARATE (ERYTHROMYCIN STEARATE)
ERYTHRO-STATIN (ERYTHROMYCIN)
ERYZOLE (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
E-SOLVE 2 (ERYTHROMYCIN)
ETHRIL 250 (ERYTHROMYCIN STEARATE)
ETHRIL 500 (ERYTHROMYCIN STEARATE)
ILOSONE (ERYTHROMYCIN ESTOLATE)
ILOSONE SULFA (ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL)
ILOTYCIN (ERYTHROMYCIN)
ILOTYCIN GLUCEPTATE (ERYTHROMYCIN GLUCEPTATE)
PCE (ERYTHROMYCIN)
PEDIAMYCIN (ERYTHROMYCIN ETHYLSUCCINATE)
PEDIAMYCIN 400 (ERYTHROMYCIN ETHYLSUCCINATE)
PEDIAZOLE (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
PFIZER-E (ERYTHROMYCIN STEARATE)
ROBIMYCIN (ERYTHROMYCIN)
R-P MYCIN (ERYTHROMYCIN)
SANSAC (ERYTHROMYCIN)
STATICIN (ERYTHROMYCIN)
T-STAT (ERYTHROMYCIN)
WYAMYCIN E (ERYTHROMYCIN ETHYLSUCCINATE)
WYAMYCIN S (ERYTHROMYCIN STEARATE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
BIT 약효분류	여드름치료제 (Acne Prep.)
ATC 코드	ANTI-ACNE PREPARATIONS FOR TOPICAL USE / D10A [코드분류상세설명] [ATC코드예측]
복지부분류코드	265 (기생성 피부질환용제 )
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	비급여 [상병코드조회] [질병코드집 다운로드]
제품성상	미황색-황색의 투명한 겔 [제형정보 확인]
포장·유통단위	10g
보관방법	차광기밀용기, 25℃ 이하

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : C등급
(tretinoin topical )

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

Pharmacokinetics

유료정보입니다.

병용금기 및 연령대금기 근거조회

[병용금기 및 연령대금기 근거조회]

복약라벨

이미지

복약설명

임산부 또는 임신계획중 복용금지

*	복약이미지는 모든 복약지도 사항을 표시한것은 아니며, 추가적으로 업데이트되거나 수정될 수 있습니다.
*	복약이미지의 표시여부는 실제 약물복용시 중요도에 따른것은 아니며 단순히 허가정보상 키워드를 기준으로 등록되었습니다.
*	귀하가 복약이미지 정보를 신뢰함은 전적으로 귀하의 책임입니다. 드럭인포는 이에 대한 어떠한 보증도 하지 않습니다.

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
Mechanism of Action	Erythromycin에 대한 Mechanism_Of_Action 정보 Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug. Tretinoin에 대한 Mechanism_Of_Action 정보 Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.
Pharmacology	Erythromycin에 대한 Pharmacology 정보 Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier, but fetal plasma levels are low. Erythromycin is not removed by peritoneal dialysis or hemodialysis. Tretinoin에 대한 Pharmacology 정보 Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).
Protein Binding	Erythromycin에 대한 단백결합 정보 Erythromycin is largely bound to plasma proteins, and the freely dissociating bound fraction after administration of erythromycin base represents 90% of the total erythromycin absorbed. Tretinoin에 대한 단백결합 정보 > 95%
Half-life	Erythromycin에 대한 반감기 정보 1.5 hours Tretinoin에 대한 반감기 정보 0.5-2 hours
Absorption	Erythromycin에 대한 Absorption 정보 Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor. Tretinoin에 대한 Absorption 정보 1-31% (topical)
Pharmacokinetics	Tretinoin의 약물동력학자료 작용발현시간 : 여드름 : 국소적용 : 2-3주 최대효과 발현시간 : 여드름 : 국소적용 : 6주 이상 흡수 : 국소 적용 : 전신 흡수는 적다. 대사 : 전신적으로 흡수된 소량은 간에서 대사된다. 소실 : 소변, 담즙을 통해 배설된다. Erythromycin의 약물동력학자료 흡수 : 다양하지만 base 형태보다 염의 형태가 더 잘 흡수된다. 일반적으로 음식물 존재시 흡수가 지연되나 ethylsuccinate염은 식직후에 복용하면 흡수가 증가된다. 흡수률의 차이로 erythromycin ethylsuccinate 200 mg는 erythromycin base 125 m와 동등한 혈중농도를 나타낸다. 생체내이용률 : 경구 : 18-45% 분포 : 태반통과, 유즙분비 뇌척수액으로의 분포는 염증이 있는 경우에도 미미하다. 뇌척수액 대 혈액의 농도 비 (%) : 정상 뇌막 : 1-12 감염된 뇌막 : 7-25 단백결합 : 75-90% 대사 : 간에서 demethylation 반감기 : 1.5-2 시간 말기 신부전환자 : 5-6 시간 혈중최고농도 도달시간 : base : 4시간 Ethylsuccinate 염 : 0.5-2.5 시간 소실 : 대부분 담즙배설되고, 2-15%가 미변화체로 신배설
Biotransformation	Erythromycin에 대한 Biotransformation 정보 Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Tretinoin에 대한 Biotransformation 정보 Hepatic
Toxicity	Erythromycin에 대한 Toxicity 정보 Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting. Tretinoin에 대한 Toxicity 정보 Not Available
Drug Interactions	Erythromycin에 대한 Drug_Interactions 정보 Alfentanil The macrolide increases the effect and toxicity of alfentanilAlprazolam The macrolide increases the effect of the benzodiazepineAminophylline The macrolide increases the effect and toxicity of theophyllineAmiodarone Increased risk of cardiotoxicity and arrhythmiasAnisindione The macrolide increases anticoagulant effectAprepitant This CYP3A4 inhibitor increases effect and toxicity of aprepitantAstemizole Increased risk of cardiotoxicity and arrhythmiasAtorvastatin The macrolide possibly increases the statin toxicityBretylium Increased risk of cardiotoxicity and arryhthmiasBromocriptine Erythromycin increases serum levels of bromocriptineBuspirone The macrolide increases the effect and toxicity of buspironeCabergoline Erythromycin increases serum levels and toxicity of cabergolineCarbamazepine The macrolide increases the effect of carbamazepineCerivastatin The macrolide possibly increases the statin toxicityCilostazol Erythromycin increases the effect of cilostazolCinacalcet This macrolide increases the serum levels and toxicity of cinacalcetCisapride Increased risk of cardiotoxicity and arrhythmiasCitalopram Possible serotoninergic syndrome with this combinationClozapine Erythromycin increases the effect of clozapineColchicine Severe colchicine toxicity can occurCyclosporine The macrolide increases the effect of cyclosporineDiazepam The macrolide increases the effect of the benzodiazepineDicumarol The macrolide increases anticoagulant effectDigoxin The macrolide increases the effect of digoxin in 10% of patientsDihydroergotamine Possible ergotism and severe ischemia with this combinationDihydroergotoxine Possible ergotism and severe ischemia with this combinationDyphylline The macrolide increases the effect and toxicity of theophyllineDisopyramide Increased risk of cardiotoxicity and arrhythmiasDivalproex sodium Erythromycin increases the effect of valproic acidDocetaxel The agent increases the serum levels and toxicity of docetaxelDofetilide Increased risk of cardiotoxicity and arrhythmiasEletriptan The macrolide increases the effect and toxicity of eletriptanEplerenone This CYP3A4 inhibitor increases the effect and toxicity of eplerenoneErgotamine Possible ergotism and severe ischemia with this combinationErlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinibImatinib The macrolide increases levels of imatinibFelodipine Erythromycin increases the effect of felodipineFluoxetine Possible serotoninergic syndrome with this combinationGefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinibGrepafloxacin Increased risk of cardiotoxicity and arrhythmiasItraconazole The macrolide increases the effect and toxicity of itraconazoleLevofloxacin Increased risk of cardiotoxicity and arrhythmiasMesoridazine Increased risk of cardiotoxicity and arrhythmiasMethylergonovine Possible ergotism and severe ischemia with this combinationLovastatin The macrolide possibly increases the statin toxicityMethylprednisolone The macrolide increases the effect of corticosteroidMethysergide Possible ergotism and severe ischemia with this combinationMidazolam The macrolide increases the efect of the benzodiazepineMoxifloxacin Increased risk of cardiotoxicity and arrhythmiasOxtriphylline The macrolide increases the effect and toxicity of theophyllinePimozide Increased risk of cardiotoxicity and arrhythmiasQuetiapine This macrolide increases the effect/toxicity of quetiapineQuinidine Increased risk of cardiotoxicity and arrhythmiasQuinidine barbiturate Increased risk of cardiotoxicity and arrhythmiasQuinupristin This combination presents an increased risk of toxicityRanolazine Increased levels of ranolazine - risk of toxicityRepaglinide This macrolide increases effect of repaglinideRifabutin The rifamycin decreases the effect of the macrolideRifampin The rifamycin decreases the effect of the macrolideRitonavir Increased toxicity of both agentsSertraline Possible serotoninergic syndrome with this combinationSibutramine Erythromycin increases the effect and toxicity of sibutramineSildenafil The macrolide increases the effect and toxicity of sildenafilSimvastatin The macrolide possibly increases the statin toxicitySirolimus The macrolide increases sirolimus levelsSotalol Increased risk of cardiotoxicity and arrhythmiasSparfloxacin Increased risk of cardiotoxicity and arrhythmiasTacrolimus Erythromycin increases the effect and toxicity of tacrolimusTerfenadine Increased risk of cardiotoxicity and arrhythmiasTheophylline The macrolide increases the effect and toxicity of theophyllineThioridazine Increased risk of cardiotoxicity and arrhythmiasVerapamil Increased risk of cardiotoxicity and arrhythmiasTriazolam The macrolide increases the effect of the benzodiazepineVardenafil The macrolide increases the effect and toxicity of vardenafilVinblastine Erythromycin increases vinblastine toxicityWarfarin The macrolide increases anticoagulant effectZafirlukast Erythromycin decreases the effect of zafirlukastErgonovine Possible ergotism and severe ischemia with this combinationEverolimus The macrolide increases everolimus levels/toxicityLincomycin Possible antagonism of action with this combinationAcenocoumarol The macrolide increases anticoagulant effect Tretinoin에 대한 Drug_Interactions 정보 Not Available
CYP450 Drug Interaction	[CYP450 Table직접조회] Erythromycin에 대한 P450 table SUBSTRATES CYP 3A4/3A5/3A7 Macrolide antibiotics: clarithromycin erythromycin NOT azithromycin telithromycin Anti-arrhythmics: quinidine Benzodiazepines: alprazolam diazepam midazolam triazolam Immune Modulators: cyclosporine tacrolimus (FK506) HIV Protease Inhibitors: indinavir ritonavir saquinavir Prokinetic: cisapride Antihistamines: astemizole chlorpheniramine Calcium Channel Blockers: amlodipine diltiazem felodipine nifedipine nisoldipine nitrendipine verapamil HMG CoA Reductase Inhibitors: atorvastatin cerivastatin lovastatin NOT pravastatin simvastatin aripiprazole buspirone gleevec haloperidol (in part) methadone pimozide quinine NOT rosuvastatin sildenafil tamoxifen trazodone vincristine INHIBITORS CYP 3A4/3A5/3A7 HIV Protease Inhibitors: indinavir nelfinavir ritonavir amiodarone NOT azithromycin cimetidine clarithromycin diltiazem erythromycin fluvoxamine grapefruit juice itraconazole ketoconazole mibefradil nefazodone troleandomycin verapamil INDUCERS CYP 3A4/3A5/3A7 carbamazepine phenobarbital phenytoin rifabutin rifampin St. John's wort troglitazone SUBSTRATES CYP 3A4/3A5/3A7 Macrolide antibiotics: clarithromycin erythromycin NOT azithromycin telithromycin Anti-arrhythmics: quinidine Benzodiazepines: alprazolam diazepam midazolam triazolam Immune Modulators: cyclosporine tacrolimus (FK506) HIV Protease Inhibitors: indinavir ritonavir saquinavir Prokinetic: cisapride Antihistamines: astemizole chlorpheniramine Calcium Channel Blockers: amlodipine diltiazem felodipine nifedipine nisoldipine nitrendipine verapamil HMG CoA Reductase Inhibitors: atorvastatin cerivastatin lovastatin NOT pravastatin simvastatin aripiprazole buspirone gleevec haloperidol (in part) methadone pimozide quinine NOT rosuvastatin sildenafil tamoxifen trazodone vincristine INHIBITORS CYP 3A4/3A5/3A7 HIV Protease Inhibitors: indinavir nelfinavir ritonavir amiodarone NOT azithromycin cimetidine clarithromycin diltiazem erythromycin fluvoxamine grapefruit juice itraconazole ketoconazole mibefradil nefazodone troleandomycin verapamil INDUCERS CYP 3A4/3A5/3A7 carbamazepine phenobarbital phenytoin rifabutin rifampin St. John's wort troglitazone
Drug Target	[Drug Target]
Description	Erythromycin에 대한 Description 정보 Erythromycin is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. [PubChem] Tretinoin에 대한 Description 정보 Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).
Dosage Form	Erythromycin에 대한 Dosage_Form 정보 Capsule, coated OralLiquid DentalLiquid OralOintment OphthalmicPowder IntravenousPowder OralPowder, for solution IntravenousPowder, for solution OralPowder, for suspension OralSuspension OralTablet Oral Tretinoin에 대한 Dosage_Form 정보 Capsule OralCream TopicalGel TopicalLiquid Topical
Drug Category	Erythromycin에 대한 Drug_Category 정보 Anti-Bacterial Agents Tretinoin에 대한 Drug_Category 정보 Antineoplastic AgentsCell Stimulants and ProliferantsKeratolytic Agents
Smiles String Canonical	Erythromycin에 대한 Smiles_String_canonical 정보 CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O Tretinoin에 대한 Smiles_String_canonical 정보 CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O
Smiles String Isomeric	Erythromycin에 대한 Smiles_String_isomeric 정보 CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O Tretinoin에 대한 Smiles_String_isomeric 정보 CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(O)=O
InChI Identifier	Erythromycin에 대한 InChI_Identifier 정보 InChI=1/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1 Tretinoin에 대한 InChI_Identifier 정보 InChI=1/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/f/h21H
Chemical IUPAC Name	Erythromycin에 대한 Chemical_IUPAC_Name 정보 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione Tretinoin에 대한 Chemical_IUPAC_Name 정보 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
Drug-Induced Toxicity Related Proteins	ERYTHROMYCIN 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Misshapen-like kinase(Mink) Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Potassium voltage-gated channel subfamily KQT member 1 (KvLQT1) Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Intercellular adhesion molecule 1 Drug:erythromycin Toxicity:pathogenesis of infusion phlebitis. [바로가기] Replated Protein:HERG Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Alanine aminotransferase Drug:erythromycin Toxicity:adverse gastrointestinal effects. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보